普洛药业(000739) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥2,101,428,825.31, representing a 6.85% increase compared to ¥1,966,705,576.05 in the same period last year[2] - Net profit attributable to shareholders decreased by 29.96% to ¥152,091,656.06 from ¥217,157,530.74 year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥135,904,532.94, down 28.30% from ¥189,535,650.14 in the previous year[2] - Total operating revenue for the first quarter of 2022 was CNY 2,101,428,825.31, an increase of 6.84% compared to CNY 1,966,705,576.05 in the same period last year[12] - Net profit for the first quarter of 2022 was CNY 152,091,656.06, a decrease of 30.03% from CNY 217,157,530.74 in the previous year[12] - Basic earnings per share for the first quarter of 2022 were CNY 0.1291, down from CNY 0.1843 in the same period last year, a decrease of 30%[14] Cash Flow - Operating cash flow increased by 15.89% to ¥171,696,287.82 compared to ¥148,153,167.43 in the same period last year[2] - The net cash flow from operating activities for Q1 2022 was ¥171,696,287.82, an increase from ¥148,153,167.43 in Q1 2021, representing a growth of approximately 15.4%[16] - Total cash inflow from operating activities amounted to ¥1,512,778,824.01, compared to ¥1,396,429,403.54 in the previous year, indicating an increase of about 8.3%[16] - Cash outflow from operating activities totaled ¥1,341,082,536.19, up from ¥1,248,276,236.11, reflecting a rise of approximately 7.4%[16] - The net cash flow from investing activities was -¥213,369,394.57, worsening from -¥25,016,560.53 year-over-year[16] - The net cash flow from financing activities increased by 78.80% to ¥363,036,069.47 from ¥203,041,368.36 year-on-year[5] - Cash inflow from financing activities reached ¥533,000,000.00, compared to ¥435,000,000.00 in the same quarter last year, marking an increase of about 22.5%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,019,157,968.42, a 9.34% increase from ¥9,163,329,850.05 at the end of the previous year[2] - The total liabilities increased to CNY 4,807,046,042.98 from CNY 4,103,324,357.05, representing a rise of 17.14%[11] - The company's total current assets as of March 31, 2022, amount to ¥6,521,432,245.87, an increase from ¥5,781,909,915.75 at the beginning of the year[9] - Cash and cash equivalents increased to ¥2,988,413,275.38 from ¥2,610,010,623.44[8] - Inventory as of March 31, 2022, is valued at ¥1,356,152,503.90, up from ¥1,249,878,604.74[9] - The company reported short-term borrowings of ¥501,225,701.15, an increase from ¥332,474,393.04[9] - Accounts payable decreased slightly to ¥1,237,962,676.03 from ¥1,300,673,202.35[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 47,191[6] - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of shares, totaling 330,941,729 shares[6] - The company has a total of 0 preferred shareholders at the end of the reporting period[7] Research and Development - Research and development expenses increased by 45.30% to ¥142,277,701.47 from ¥97,918,833.44 year-on-year[5] - Research and development expenses increased to CNY 142,277,701.47, compared to CNY 97,918,833.44, marking a year-over-year increase of 45.16%[12] Other Information - The report indicates that there are no significant new strategies or product developments mentioned in the current quarter[8] - The company reported a decrease in tax expenses to CNY 29,796,752.46 from CNY 42,198,139.45, a reduction of 29.36%[12] - Other comprehensive income after tax was CNY 14,776.38, compared to a loss of CNY 54,155.88 in the previous year, indicating a positive turnaround[14] - The company did not conduct an audit for the Q1 2022 report[18]